The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 33 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Wickramasekara: Major pharma increasingly licenses drug molecules from China
“We've seen this huge uptick in pharma going to China and buying molecules that they typically would have bought from American biotechs.”
Wickramasekara: Clinical trial optimization is a red herring versus molecule quality
“People get very focused on clinical trials because they're like the biggest line item. And they're important, don't get me wrong, but I think it's actually a bit of a red, red herring. Where, ah, yes, there are operational problems. Like, some studies are desi…”
Wickramasekara: GLP-1s will probably be the best-selling drugs of all time
“And then all of a sudden, like we have this category defining medicine that's going to go on to probably be the best selling drug of all, all time.”
Wickramasekara: AI in scientific discovery will focus on augmentation over autonomy next 1-2 years
“While I would love for that to happen, and I'm maybe more optimistic on a longer time scale, we will get there. I think in the short term, I'm next one to two years, which, you know, already feels like an eternity in AI time. I'm a little bit more bullish on s…”
Wickramasekara: Most Biotech Researchers Are Not Yet Using Much AI in R&D
“Most people aren't really using that much AI and R&D yet. They all want to, they're primed to, but there's a lot of concerns about accuracy, IP, security, legal. And I think the farther you go from SF, the like, Larger those concerns, concerns get.”
Wickramasekara: Pure AI biology model companies must morph into biopharma
“I think it's unlikely, it's possible, but it's unlikely that sort of, hey, they're just gonna remain pure model companies who just do deals with pharma, where pharma, you know, pays them a hundred million dollars upfront or something like that, and they have f…”
Wickramasekara: 5 to 10 customers represent what an entire vertical industry needs
“I find that having five, 10 customers is actually like a pretty representative model for what the entire industry needs.”
Wickramasekara: Recent years in biotech equal a dot-com level bust
“We're probably like the last couple of years are probably like the equivalent of like the dot com bust happening for biotech.”
Wickramasekara: Novel biotech modalities are in a trough of disillusionment
“I think investors and companies got very excited and put a lot of money into these categories, and we're kind of in the trough of disillusionment for some of them now.”
Wickramasekara: Next decade of biotech will focus on speed and cost
“If the last decade was about sort of biologics and these new modalities, I think the next is going to be about speed and cost.”
Wickramasekara: Prescription drugs account for 9% of US healthcare spending
“I think nine percent of healthcare spent, prescription drug sales are nine percent of healthcare spending in the U.S.”
Wickramasekara: Obesity drugs were completely unfundable five years ago
“So GLP-Ins obviously have just transformed obesity as, like, a treatable disease when, by the way, it was, like, a totally unfundable category of things, like, five years ago.”
Wickramasekara: Much of scientific research is lost to institutional folklore
“And so there's so much of science that lives in like folklore and institutional knowledge, and that's kind of lost over time.”
Wickramasekara: High-stakes AI requires human accountability to bear legal liability
“And truthfully, like at the end of the day, you probably like, you know, with a radiologist, you probably need a human to be accountable For those decisions, it's not just about the technology. Like, someone, someone's gotta be there to, like get sued if somet…”
Wickramasekara: Biology AI has powerful models but lacks a ChatGPT-like interface
“I think we're like, we've got GPT, but there's no chat. Like, that, that's kind of how I think about it. Like, I think the chat, and I mean chat metaphorically, like, that was the interface that made things really take off in, in software. And I don't think it…”
Wickramasekara: 90% of vertical AI is workflow translation and building trust
“I think in a vertical, I think 90% of the work is actually, like, translation. It's taking something and making science, making sure scientists trust it, it's the right point in their workflow, it's easy to use, and it's accurate.”
Wickramasekara: Large pharma is piloting AI without organizational transformation yet
“Most of the
Large pharma at this point that I've worked with, like, you know, they've got co-pilot and things like that, and they're doing a lot of pilots of different technologies, but I haven't seen their orgs transformed yet.”
Wickramasekara: Large pharma generates model-training data at scale startups cannot match
“They can generate data to train their own models at a scale that most biotech startups can't match.”
Wickramasekara: Large pharma will produce unique proprietary predictive models
“I think while it's early on sort of the agentic how we work side, I think you're going to see very unique models come out of pharma where their computational scientists are building interesting predictive models that, you know, similar to what's happening in t…”
Wickramasekara: AI drug development requires optimizing every pipeline step, not one-shot generation
“My mental model is like, there are so many steps. Those steps are all cumbersome and difficult. And this is a game of like making each single thing better. And, like, some of the steps matter more than others, like, having the right target or having, like, a g…”
Wickramasekara: Biopharma rarely buys early data due to lack of trust
“You see very, very few transactions of data. That's because no one trusts anyone else's data. You wait till there's a clinical trial, and the data is positive, and you buy the molecule. But you'd think that you'd see a lot more selling of data before that. But…”
Wickramasekara: AI will convert life sciences skeptics to structured data tools
“But now with like AI, one, I think the benefits are a much more immediately obvious to everyone. And so that's going to be this amazing tailwind to try to like do better here. And I think it will convince a lot of people who might have been skeptics in the pas…”
Wickramasekara: Science is uniquely structured to benefit from LLM architectures
“I go back to that sort of returns to intelligence piece where I think science is a problem that has some shape to it that really benefits from the LLM architecture. Like you just think about the corpus of scientific literature as like this vast pool of unstruc…”
Wickramasekara: A co-founder's true power lies in moral authority
“I feel like the power of being a co-founder is actually just in moral authority”
Benchling CEO: Software engineers with bio expertise effectively do not exist
“If I was only hiring like software people who knew bio, I would have like exhausted the pool 10 years ago. It just doesn't exist. We have to take the software people, take the science people, make them sit together.”
Wickramasekara: Biopharma is underappreciated because it communicates as faceless companies
“I think like because sort of the way they communicate is much more about almost these like faceless companies rather than the people, I think it's like easy to hate on them and underappreciate. So I think they need to tell their story and go direct.”
Benchling serves 1,300 biopharma companies and 7,000 academic institutions
“Today we work with about 1300 biotech and pharma companies scientists at over 7000 academic institutions, universities, all, all around the world. And our software powers, you know, household names like Moderna and Sanofi and Eli Lilly and Regeneron, but also …”
Wickramasekara: J&J's cancer drug Carvykti originated from China's Legend Biotech
“Johnson and Johnson partnered with a Chinese biotech called Legend Biotech... They've taken it, and it's a, it's actually a cancer immunotherapy... For multiple myeloma. And like that, that medicine is very commercially successful and widely distributed in the…”
Wickramasekara: The core science behind GLP-1s has existed since the 1990s
“And so, but the core science for GLP ones was kind of sitting on the shelf in some sense, like it's been known since like the nineties.”
Wickramasekara: Benchling released a deep research AI agent over lab data
“And so we've released this deep research agent. It works similar to the deep research agents from Anthropic and other foundation labs. But what it does is it works over Benchling data with the context of the Benchling data model.”
Wickramasekara: Benchling AI saved a customer an 8-month redundant mouse study
“We had a customer that was getting ready to run some mouse studies, and they were looking at 20 different mouse models, and they used a deep research our deep research capability to look at all the historical mouse studies that they had run, and it turned out …”
Wickramasekara: Eli Lilly launched TuneLab to share AI models via federated learning
“Eli Lilly put out this announcement about a project they have called TuneLab, where they're taking their internal models and making them available to the broader scientific ecosystem. So a farmer company is saying, hey, you can use our models, but it's give to…”
Wickramasekara finds agentic coding tools the most exciting non-bio AI application
“And like, I've tried some of the new agentic coding tools lately, and it's just like, on a personal level, fun to just Feel like the whimsy of being able to build something very quickly again. It's like that. That's pretty cool. That's probably the one I'm mos…”